Academic literature on the topic 'Pharmaceutical industry Australia Evaluation'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical industry Australia Evaluation.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Pharmaceutical industry Australia Evaluation"
1
Buxton, Meredith, Brian Alexander, Donald Berry, Webster Cavenee, Howard Colman, John de Groot, Benjamin Ellingson, et al. "CTNI-38. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA." Neuro-Oncology 24, Supplement_7 (November 1, 2022): vii80. http://dx.doi.org/10.1093/neuonc/noac209.303.
Full textAbstract:
Abstract BACKGROUND GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, international, seamless Phase 2/3 response adaptive randomization platform trial designed to rapidly identify experimental therapies that improve overall survival and confirm efficacious experimental therapies and associated biomarker signatures to support new drug approvals and registration. GBM AGILE is a collaboration between academic investigators, patient organizations and industry to support new drug applications for newly diagnosed and recurrent GBM. METHODS The primary objective of GBM AGILE is to identify therapies that effectively improve the overall survival in patients with ND or recurrent GBM. Bayesian response adaptive randomization is used within subtypes of the disease to assign participants to investigational arms based on their performance. Operating under a Master Protocol, GBM AGILE allows multiple drugs from different pharmaceutical/biotech companies to be evaluated simultaneously and/or over time against a common control. New experimental therapies are added as information about promising new drugs is identified while therapies are removed as they complete their evaluation. The master protocol/ trial infrastructure includes efficiencies through an adaptive trial design, shared control arm and operational processes to serve the goal of helping patients receive optimal care in a fast and efficient manner. GBM AGILE has screened over 1200 patients and enrollment rates are 3 to 4 times greater than traditional GBM trials, with active sites averaging 0.75 to 1 patients/sites/month. There are 41 active sites in the US, 4 active sites in Canada and 3 active sites in Europe with more sites anticipated to open across 5 countries in Europe. Expansion to China and Australia are under progress. Through the use of improved and flexible processes, GBM AGILE serves as a global trial that supports the efficient and rapid incorporation and evaluation of new experimental therapies for patients with GBM.Clinical trial information: NCT03970447.
2
Buxton, Meredith Becker, Brian Michael Alexander, Donald A. Berry, Webster K. Cavenee, Howard Colman, John Frederick De Groot, Benjamin M. Ellingson, et al. "GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): TPS2579. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps2579.
Full textAbstract:
TPS2579 Background: Glioblastoma (GBM) is an aggressive brain tumor with few effective therapies and is invariably fatal. Developing new therapies for patients with GBM requires focused interaction between industry, academia, nonprofits, patient advocacy, and health authorities, and novel approaches to clinical trials. Industry is wary of developing drugs for GBM due to the high failure rate and high cost of drug development. GBM Adaptive Global Innovative Learning Environment (GBM AGILE) Trial was designed by over 130 global key opinion leaders in consultation with health authorities to provide an optimal mechanism for phase II/III development in GBM. The Sponsor of GBM AGILE is the Global Coalition for Adaptive Research (GCAR), a non-profit organization. GCAR’s mission is to speed the discovery and development of treatments for patients with rare and deadly diseases by serving as sponsor of innovative trials. Methods: GBM AGILE is an international, seamless phase II/III platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM. Its goals are to identify effective therapies for GBM and match effective therapies with patient subtypes, with data generated to support regulatory filing for new drug applications. Bayesian response adaptive randomization is used within subtypes of the disease to assign participants to investigational arms based on their performance. The primary endpoint is overall survival. The trial is being conducted under a master Investigational New Drug Application/Clinical Trial Agreement and Master Protocol, allowing multiple drugs/drug combinations from different pharmaceutical companies to be evaluated simultaneously and/or over time. The plan is to add experimental therapies as new information is identified and remove therapies as they complete their individual evaluation against a common control. GBM AGILE received IND approval from the FDA in April 2019, enrolling its first patient in June 2019. Site activation is ongoing in the US, with approximately 40 US planned. The trial received CTA approval from Health Canada in January 2020. Expansion to Europe, China, and Australia is also underway. Clinical trial information: NCT03970447 .
3
Wu, Allan Ya-Huan, Victoria Janine Little, and Brian Low. "Inbound open innovation for pharmaceutical markets: a case study of an anti-diabetic drug in-licensing decision." Journal of Business & Industrial Marketing 31, no. 2 (March 7, 2016): 205–18. http://dx.doi.org/10.1108/jbim-10-2013-0236.
Full textAbstract:
Purpose – This paper aims to increase understanding of how firms can more effectively identify valuable and profitable innovations in the pharmaceutical industry and to identify the issues and challenges posed by current managerial decision-making practices. Design/methodology/approach – A case study of a single project is presented: a drug in-licensing decision made by a team of three managers in a large Australian pharmaceutical firm. Using participant-observation, interviews and archival analysis, the authors followed the managers as they identified and evaluated 122 late-stage anti-diabetic drug variants for further development. Findings – The managers used decision heuristics to arrive at a short list of three drugs from a choice set of 122. While the process was ostensibly rational and systematic, there was evidence of data quality issues, misleading mental models and cognitive bias. The authors concluded a high probability of accepting a poor candidate or rejecting a stronger candidate (i.e. making Type I and II errors). Research limitations/implications – This paper focuses on initial market and technology evaluation stage only (i.e. not commercialization) and is a single case study design; therefore, care should be taken in generalizing to other decisions or other contexts. This paper highlights the need for further research integrating organizational decision-making and open innovation from a multi-disciplinary perspective. Practical/implications – This paper raises awareness of potential decision-making pitfalls and includes a detailed audit framework to support improved managerial decision processes and double rather than single loop learning. Social/implications – The findings support better decision-making and therefore supports higher quality drug selection and development, leading to improved population health outcomes. Originality/value – Multi-disciplinary, draws attention of marketing and new product development scholars to open innovation research. It adds to knowledge about open innovation practices at the project level. It also provides an extended model of market opportunity analysis for high technology markets.
4
Raycheva, Ralitsa, and Rumen Stefanov. "VP81 Health Technology Assessment And Rare Disease Decision Making: Focus On Orphan Drugs." International Journal of Technology Assessment in Health Care 33, S1 (2017): 186–87. http://dx.doi.org/10.1017/s0266462317003518.
Full textAbstract:
INTRODUCTION:Health Technology Assessment (HTA) is applied to determine the value of innovative technologies. It usually relies on robust assessment of the clinical cost-effectiveness of the technology, while clinical and economic evidence required for this purpose are often not available for orphan drugs (OD) (1,2). The objective of the study is to undertake a systematic comparison between HTA agencies worldwide in order to identify similarities and differences in the methods and processes in HTA of OD.METHODS:A cross-sectional web-based survey was conducted between September 2013 and May 2015. The data were obtained from a semi-structured questionnaire. We received responces from 161 HTA organizations based in 39 countries.RESULTS:HTA of OD is performed by agencies in South America (38.5 percent), followed by agencies in Australia (37.5 percent) and Europe (36.1 percent). The agencies in high income countries produce more assessments of OD (36.8 percent), which in 31.2 percent they determine as innovative technologies compared with 11.8 percent of the units based in low income countries and active in OD assessment (11.1 percent). We prove association (p< .05) between (i) the type of HTA and income per capita; the level at which the organization operates; its main activity; and the level of recommendation dissemination; (ii) the main target group and consumers of the final HTA product; the stage of evolution of the technology, on which it is likely to be assessed; and approaches to identify innovative technologies. The most active in the preparation of HTA reports are biomedical companies or other organizations in the private sector (50.0 percent) and organizations in the pharmaceutical and/or medical industry (66.7 percent). HTA bodies that assess OD develop (36.0 percent) and distribute recommendations (35.9 percent) nationally; their main activity is to produce guidelines for good clinical practice (46.9 percent). Agencies that perform OD assessment are active in evaluation of innovative (37.2 percent) and emerging (35.9 percent) technologies, which are able to be identified by developing early warning systems (32.0 percent).CONCLUSIONS:Making coverage decisions based on HTA recommendations control the technologies introduction into the healthcare system, that is why it's very important that this tool is properly adjusted to the specific needs of OD assessment (3).
5
Weller, M., B. Ellingson, B. Alexander, P. Wen, E. Sulman, H. Colman, D. Berry, et al. "P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma." Neuro-Oncology 24, Supplement_2 (September 1, 2022): ii73. http://dx.doi.org/10.1093/neuonc/noac174.254.
Full textAbstract:
Abstract Background GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, international, seamless Phase 2/3 Response Adaptive Randomization platform trial designed to rapidly identify experimental therapies that improve overall survival and confirm efficacious experimental therapies and associated biomarker signatures to support new drug approvals and registration. It is a collaboration between academic investigators, patient organizations and industry, under the sponsorship of the non-profit organization, Global Coalition for Adaptive Research, to support new drug applications for newly diagnosed and recurrent GBM. Material and Methods The primary objective of GBM AGILE is to identify therapies that effectively improve overall survival in patients with newly diagnosed or recurrent GBM. Bayesian response adaptive randomization is used within subtypes of the disease to assign participants to investigational arms based on their performance. Operating under a master protocol, GBM AGILE allows multiple drugs from different pharmaceutical companies to be evaluated simultaneously and/or over time against a common control arm. Based on performance, a drug may graduate and move to a Stage 2 (Phase 3) within the trial, and the totality of the data can be used for a new drug application and registration process. New experimental therapies are added as information about promising new drugs is identified while other therapies are removed as they complete their evaluation. The master protocol/ trial infrastructure includes efficiencies through an adaptive trial design, shared control arm and operational processes such as risk-based monitoring and enhanced remote activities. With its adaptable structure, GBM AGILE has continued trial activation, inclusion of new investigational therapies, and enrollment globally through the challenges of a global pandemic.GBM AGILE provides an efficient mechanism to screen and develop robust information regarding the efficacy of proposed novel therapeutics and associated biomarkers for GBM and to quickly move therapies and biomarkers into clinic. GBM AGILE received initial approval from the United States FDA in April 2019, and in Europe through the Voluntary Harmonization Procedure (VHP) in April, 2021. As of 2022, AGILE has screened over 1000 patients studying multiple investigational treatments. Enrollment rates are 3 to 4 times greater than traditional GBM trials, with active sites averaging 0.75 to 1 patients/site/month. Currently, there are 41 sites activated in the US, 4 in Canada and 2 in Switzerland and an estimated 24 sites yet to open in Germany, France, Switzerland, Italy and Austria. In addition to the continued expansion in Europe, effort is undergoing to extend the trial to China and Australia as well. Clinical trial information: NCT03970447
6
Graser, H.-U., B. Tier, D. J. Johnston, and S. A. Barwick. "Genetic evaluation for the beef industry in Australia." Australian Journal of Experimental Agriculture 45, no. 8 (2005): 913. http://dx.doi.org/10.1071/ea05075.
Full textAbstract:
Genetic evaluation for beef cattle in Australia has been performed using an animal model with best linear unbiased prediction since 1984. The evaluation procedures have evolved from simple to more complex models and from few to a large number of traits, including traits for reproduction, growth and carcass characteristics. This paper describes in detail the current beef cattle genetic evaluation system ‘BREEDPLAN’ used for the Australian beef cattle industry, the traits analysed and underlying models, and presents a short overview of the challenges and planned developments of coming years.
7
Borra Vamsi, Hemanth Kumar S, Patel P R, and Gowrav M P. "Vendor Qualification and Evaluation in Pharmaceutical Industry." International Journal of Research in Pharmaceutical Sciences 11, no. 2 (April 18, 2020): 1987–94. http://dx.doi.org/10.26452/ijrps.v11i2.2129.
Full textAbstract:
To deliver a high quality and safe medicines, it is a must to certify the vendor according to the GMP requirement. This qualification is done to prevent the adverse events, prevent the recalls or serious illness or death due to the low standard quality of manufactured medicines. Vendor qualification is the process by which a vendor is assessed to determine, if it can provide the required goods or services to the standards that the purchasing company requires. This article explains about the detailed procedure for qualifying raw material vendors, packaging vendors and service providers. This also explains the vendor assessment and the reassessment. Vendor re-assessment must be carried out at least once a year for each packaging material and the raw material. The manufactured part number is used for tracking. Supply Chain Management team (SCM) should request the QA department to generate Manufacturing Part Number. Explained about the vendor rating. The vendor must be disqualified if the batch will not adhere to specification of critical tests. For further evaluation and investigation, vendor must be once again qualified. Vendor must be informed regarding the removal and the reasons must be explained clearly. Vendor Relationship Management (SRM), is systematic planning and managing of all interactions with suppliers to maximize its value.
8
Hirst, Christine A. "GOVERNMENT INITIATIVES IN THE DEVELOPMENT OF A PHARMACEUTICAL INDUSTRY IN AUSTRALIA." Clinical and Experimental Pharmacology and Physiology 19, no. 1 (January 1992): 57–61. http://dx.doi.org/10.1111/j.1440-1681.1992.tb00398.x.
Full text
9
Lau, Edith, Alice Fabbri, and Barbara Mintzes. "How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study." Australian Health Review 43, no. 4 (2019): 474. http://dx.doi.org/10.1071/ah17288.
Full textAbstract:
Objective The aim of this study was to investigate how health consumer organisations manage their relationships with the pharmaceutical industry in Australia. Methods We identified 230 health consumer organisations that received pharmaceutical industry support from 2013 to 2016 according to reports published by Medicines Australia, the industry trade association. A random sample of 133 organisations was selected and their websites assessed for financial transparency, policies governing corporate sponsorship and evidence of potential industry influence. Results In all, 130 of the 133 organisations evaluated received industry funding. Of these 130, 68 (52.3%; 95% confidence interval (CI) 43.4–61.1%) disclosed this funding. Nearly all (67; 98.5%) reported the identity of their industry donors, followed by uses (52.9%), amount (13.2%) and proportion of income from industry (4.4%). Less than one-fifth (24/133; 18.0%; 95% CI 11.9–25.6%) had publicly available policies on corporate sponsorship. Six organisations (7.2%; 95% CI 2.7–15.1%) had board members that were currently or previously employed by pharmaceutical companies, and 49 (36.8%; 95% CI 28.6–45.6%) had company logos, web links or advertisements on their websites. Conclusion Industry-funded health consumer organisations in Australia have low transparency when reporting industry funding and few have policies governing corporate sponsorship. Relationships between health consumer organisations and the industry require effective actions to minimise the risks of undue influence. What is known about this topic? Pharmaceutical industry funding of health consumer organisations is common in the US and Europe, yet only a minority of such organisations publicly disclose this funding and have policies regulating their relationships with industry. What does this paper add? Industry-funded health consumer organisations in Australia have inadequate financial transparency and rarely have policies addressing corporate funding. Organisations that have received more industry funding are more likely to report it publicly. What are the implications for practitioners? Robust policies addressing corporate sponsorship and increased transparency are needed to maintain the independence of health consumer organisations. Governments may also consider regulating non-profit organisations to ensure public reporting of funding sources.
10
АЛЬМУРЗАЕВА, А. А., К. С. ЖАКИПБЕКОВ, У. М. ДАТХАЕВ, М. З. АШИРОВ, and З. А. ДАТХАЕВА. "COMPETITIVENESS OF PHARMACEUTICAL INDUSTRY: INDICATORS AND EVALUATION CRITERIA." Farmaciâ Kazahstana, no. 2 (June 14, 2022): 4–9. http://dx.doi.org/10.53511/pharmkaz.2022.26.21.001.
Full textAbstract:
Актуальность. На современном этапе развития рыночных отношений эффективность деятельности аптечных организаций как субъектов фармацевтического рынка во многом зависит от уровня их конкурентоспособности. Методы. При подготовке данного исследования применялись сравнительные, описательные, системные, ретроспективные методы, SWOT-анализ. Результаты. Для развития фармацевтической промышленности в Казахстане предприятиям необходимо направить свою стратегию на рост основных показателей и целевых индикаторов: создание и модернизация высокопроизводительных рабочих мест; увеличение производительности труда в фармацевтической и медицинской отрасли; увеличение доли высокотехнологичной и наукоемкой продукции в общем объеме производства; доля лекарственных средств отечественного производства; экспорт лекарственных средств и медицинских изделий. Выводы. Для достижения этих целей руководителям производств необходимо использовать научно обоснованные подходы, которые позволят определить и повысить уровень конкурентноспособности собственной организации. Relevance. At the present stage of development of market relations, the effectiveness of pharmacy organizations as subjects of the pharmaceutical market largely depends on the level of their competitiveness. Methods. In preparing this study, comparative, descriptive, systematic, retrospective methods, SWOT analysis were used. Results. For the development of the pharmaceutical industry in Kazakhstan, enterprises need to direct their strategy towards the growth of key indicators and target indicators: creation and modernization of high-performance jobs; increase in labor productivity in the pharmaceutical and medical industries; increase in the share of hightech and science-intensive products in the total volume of production; share of domestically produced medicines; export of medicines and medical devices.
Dissertations / Theses on the topic "Pharmaceutical industry Australia Evaluation"
1
Beyer, Lorraine R. "Heroin importation and higher level drug dealing in Australia : opportunistic entrepreneurialism /." Connect to thesis, 2005. http://eprints.unimelb.edu.au/archive/00001612.
Full text
2
Ma, Wing-yan. "Contract research organizations : performance and evaluation of services /." View the Table of Contents & Abstract, 2006. http://sunzi.lib.hku.hk/hkuto/record/B38030561.
Full text
3
Farzandi, Gholamhossein. "Evaluation of the post-WTO sustainability of the pharmaceutical industry in Iran." Thesis, Cardiff University, 2011. http://orca.cf.ac.uk/54417/.
Full textAbstract:
The outcome of joining the WTO and implementing TRIPS agreement has caused a never-ending dispute in terms of both positive and negative perspectives. Patient's access to essential medicines and sustainability of the domestic pharmaceutical industry are two important relevant topics in the developing countries. Two major consequences are trade liberalisation and enforcing an international intellectual property rights. The immediate impact will be free flow of medicines from the developed countries in the case of innovative drugs and more recently from India and China for cheap commodity medicines that are supported by the internationally enforceable intellectual property protections. The aim of the study was therefore to evaluate sustainability of the pharmaceutical industry in Iran post WTO agreement using the readiness index. In the absence of previously developed instruments, two study tools were developed and validated in the course of this study namely WTO pharmaceutical Industry (PI) Impact Rating Scale and Pharmaceutical Industry Transition Instrument (PITI). Using the Delphi technique, an expert panel consisting of academics, industry senior managers and regulators identified 29 parameters that the study should focus on generating consensus for the industry in preparation of joining the WTO. The top 6 parameters included importation tariff, management knowledge, training, R&D, customer satisfaction and patent review. The study was then carried out throughout the industry to evaluate the current situation and future importance of the identified parameters that were restructured in 66 statements of the PITI. The outcomes of the studies reported in this thesis suggest that with the current situation in the pharmaceutical industry in Iran, it is unlikely that the industry will be able to cope with the post-WTO challenges to deliver the growth needed to underpin its long term sustainability. The compliance of the industry with the requirements of the WTO at the current situation was concluded to be "unsatisfactory" for the majority of the PITI statements using binomial test (p<0.05).
4
Letsitsi, Ezekiel Tebogo. "Waste management in the pharmaceutical industry : an evaluation report of Dr Reddy's Laboratories." Thesis, Rhodes University, 2013. http://hdl.handle.net/10962/d1001872.
Full textAbstract:
The pharmaceutical industry must worry about managing pharmaceutical waste as it poses a health risk to human beings and its presence in the environment can also contribute to loss of biodiversity. Ngwuluka, Ochekpe, and Odumosu (2011: 11259) state that “Pharmaceuticals, though used to treat and manage diseases, are poisons, which justify the growing concerns about their presence in the environment.” Various forms of pharmaceutical waste exist, Ngwuluka et al. (2011) identified the following forms of pharmaceutical waste: Expired dosage forms, non-reworkable formulations, spilled pharmaceuticals, rejected active pharmaceutical ingredients, expired active pharmaceutical ingredients, and wastewater resulting from the water used for process operations during manufacturing and could come from the water used to clean equipment, pipes and floors, and would contain amongst other materials, chemicals and active pharmaceutical ingredients (APIs). A review on the pharmaceutical industry and the progress they have made in environmental management by generating health, safety and environmental programs, preventing pollution, waste minimization, recycling and reusing materials, investing in projects and facilities to ensure environmental sustainability have been established (Berry & Rondinelli, 2000). Dr. Reddy’s Laboratories is an Indian based pharmaceutical company which imports, markets and sells medicines in South Africa. Dr. Reddy’s has plans to set up a manufacturing plant in South Africa. The purpose of this study is to research waste management practices at Dr. Reddy’s plant in India and to draw parallels between India’s and South Africa’s waste legislation. This is to enable Dr. Reddy’s to review all aspects of its waste management systems, in order to revise where necessary and to improve the overall achievement of its waste management objectives in order to become a more sustainable organisation and to meet South African Waste legislation before setting up a plant in South Africa. 3 ii. Objective of the Evaluation Report The purpose of this research is to evaluate and analyse the development and implementation of a waste management system in a pharmaceutical company, specifically Dr. Reddy’s Laboratories. This is primarily to enable the company to review and analyse all aspects of waste management pertaining to pharmaceutical manufacturing and to revise or improve where necessary to ensure adherence to waste regulations as outlined by government. The following research goals have been also been identified: To identify and describe waste management practices at Dr. Reddy’s Laboratories, on the inherent assumption by the researcher that the company has a successful waste management strategy that would need to be reviewed to identify areas of improvement before expanding manufacturing facilities into South Africa. To evaluate, assess and compare similarities and/or differences between the identified South African Legislation for Waste Management with those identified during research conducted at Dr. Reddy’s iii. Importance of the Research Conducted Waste Management is important in that it not only removes from the environment, substances that can be harmful to humans and animals but it also enables an organisation to be more sustainable. According to Seadon (2010: i) “Integrated waste management is considered from a systems’ approach, with a particular emphasis on advancing sustainability”. The study will provide guidance to senior management, shop floor managers and employees who work in Dr. Reddy’s manufacturing plants as well as overall employees at Dr. Reddy’s on how to successfully implement a Waste Management programme to enhance sustainability at the organisation and realise the benefits to the organisation of being more sustainable. Weybrecht (2010) identified the following benefits that companies could gain by adopting sustainable waste management practices: reduced costs, resource preservation, keeping up with legislation, enhanced reputation, business differentiation from competitors, and attraction and retention of quality employees, and customer need satisfaction amongst many other benefits. This research needs to address the gap in analysing waste management practices (with more emphasis on waste treatment, waste minimisation, re-use, recycling and disposal), and implementation and understanding of waste management in the pharmaceutical industry as prior research was done mostly in other chemical industries and not to a large scale in the pharmaceutical industry. South African Waste Legislation, Indian Waste Legislation (as Dr. Reddy’s is based in India), as well as International Pharmaceutical Waste Management Guidelines, and International Pharmaceutical Good Manufacturing Practices provide a framework and benchmark of leading pharmaceutical waste management practices that can guide Dr. Reddy’s Laboratories’ leadership into integrating their waste management practices into their plans of setting up a manufacturing plant in South Africa. 5. Research Methodology This is evaluation research in the form of a case study and the data collection method employed is the conduction of a survey through questionnaires. The evaluation research also involves a document analysis of the organisation’s 2011 and 2012 annual reports, Dr. Reddy’s 2010 Sustainability Report as well as literature compiled by the organisation’s Corporate Communications Division. The research would also include review of existing literature on waste management. v. Structure of Dissertation This dissertation consists of three sections. Section 1: The Evaluation Report The section introduces the research area, provides the objectives of the research, provides contextual background information and describes the rationale for conducting the research. This section further describes Dr. Reddy’s waste management practice as outlined in relevant company documentation; it is also intended to highlight the specific waste management processes that were followed in the formulation and implementation of the waste management strategy. This section further describes the sample and presents the results of the survey, where the results are collated and reviewed in the context of the criteria set in the South African Waste Legislation, Indian Waste Legislation, as well as in International Pharmaceutical Waste Management Guidelines, and International Pharmaceutical Good Manufacturing Practices. The overall findings of this case study suggest that although management at Dr. Reddy’s are satisfied with waste management practices and results achieved at it manufacturing plant, there is however dissatisfaction amongst employees who believe the organisation has not successfully disseminated information and sufficiently trained them on waste management policies, processes and practices. There is therefore a desire amongst employees to be trained and to see the company improve on its waste management processes, this desire is a very important attribute as it indicates that employees at Dr. Reddy understand and are committed to the importance of waste management. Future research should be conducted to measure the legal impact of non-compliance to legislation governing waste management in the pharmaceutical company. Section 2: Literature Review The objective of the literature review is to provide a critical assessment and evaluation of previous research in the field of waste management in general as prior research was done mostly in other industries and not to a large scale in the pharmaceutical industry. The literature review evaluates the key elements of an effective waste management strategy implementation and is followed by a review of literature pertaining to the description of Pharmaceutical waste. Section 3: Research Methodology This section presents a description of how the work in this research was conducted. It presents the research process followed in compiling this case study, represented by the aims and objectives, research methodology and design, data collection techniques and data analysis.
5
Sweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme." full-text, 2008. http://eprints.vu.edu.au/1960/1/sweeny.pdf.
Full textAbstract:
This thesis investigates the contribution to the growth in expenditure on medicines listed on the Pharmaceutical Benefits Scheme (PBS) from three inter-related sources: (i) the addition of new medicines offering an expanding range of treatments for disease, (ii) PBS processes for determining the prices of medicines and their conditions of listing and (iii) the demand by patients for PBS medicines. In doing so it uses trend analysis presented in both tabular and graphic form, expenditure decomposition techniques based on index and indicator numbers, and econometric analysis. Using novel techniques and interpretations, it addresses some key aspects of decomposition analysis including the treatment of new and disappearing goods and the potential bias arising from changing market shares among substitutable medicines. The analysis is undertaken for the period from 1991-92 to 2005-06. An important consequence of the cost-effectiveness and reference pricing techniques used by the PBS, is that the quantity index calculated within the decomposition of PBS expenditure can be interpreted as a measure of the quality-adjusted amount of medicines consumed by patients. This is virtually equivalent to the growth in expenditure of about 12% per annum. On average prices of medicines fell over time, modestly in nominal terms and to a greater extent in real terms. Based on the results of econometric analysis, new evidence is presented on the relative influences of copayments, safety net limits, the number of PBS medicines listed and their conditions of listing on the demand for PBS medicines by different categories of patients. Elasticities with respect to patient price are in the range -1.1 to -1.4 for General Non-Safety Net patients and in the range -0.5 to -0.9 for Concessional Non-Safety Net patients.
6
Ma, Wing-yan, and 馬詠恩. "Contract research organizations: performance and evaluation of services." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B39724888.
Full text
7
Uwais, Syed Muhammad. "Integration of expert system and analytic hierarchical process for the selection and evaluation of R&D projects in the pharmaceutical industry." Ohio : Ohio University, 1995. http://www.ohiolink.edu/etd/view.cgi?ohiou1178823422.
Full text
8
Hindocha, Darsha. "The evaluation of capillary electrochromatography (CEC) for use within a regulated environment in the pharmaceutical industry." Thesis, Imperial College London, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.399525.
Full text
9
Trushin, Eshref. "Evaluation of incentives for R&D in the pharmaceutical industry with applications for neglected diseases." Thesis, Queen Mary, University of London, 2011. http://qmro.qmul.ac.uk/xmlui/handle/123456789/1285.
Full textAbstract:
This thesis is concerned with the development of incentives for pharmaceutical R&D, specifically for neglected diseases. The following approaches are adopted. The short-term effects of the recent cost-containment reforms on seven financial indicators related to firms‘ R&D in Denmark, Germany, France, Japan, and the US are estimated. The dataset represents a panel data of financial statements of 1306 pharmaceutical firms for the period 1997-2007. National pharmaceutical expenditures, population, availability of credit, patent applications, and regulatory quality have been controlled for. The average treatment effects on the treated are econometrically estimated with before-after comparisons, two difference-in-differences (DiD) and three matching DiD methods. Impacts of liquidity constraints on R&D and investment are estimated with dynamic panel methods. Using frontier modelling, technical production inefficiencies are estimated and tested for independence from the stringency of national regulation. The major findings of this dissertation are: R&D indicators tend to be persistent despite the regulatory changes; tighter cost-containment regulations appear not to be associated with technical efficiency or R&D intensity of firms; cash flow has a positive effect on pharmaceutical R&D of small and young firms, but not on physical investment. Improved access to clean water appears to be the most important factor in the reduction of the neglected diseases‘ burden; evaluation of R&D schemes for neglected diseases based on 17 criteria indicates insufficient performance of the existing proposals and a number of recommendations to design better incentives are substantiated. Based on this analysis, I have designed a new hybrid public-private partnership model for financing R&D in the form of a prize screening mechanism, which relies on the innovative effort of small firms by reducing entry barriers and moral hazard problems.
10
Grobler, Christa. "Evaluation of sales team effectiveness in a South African pharmaceutical company." Thesis, Stellenbosch : Stellenbosch University, 2002. http://hdl.handle.net/10019.1/52836.
Full textAbstract:
Thesis (MBA)--Stellenbosch University, 2002.Some digitised pages may appear illegible due to the condition of the original hard copy.
ENGLISH ABSTRACT: A few years ago, pharmaceuticalcompanies were more inclined to look at business from the inside out. The principal focus was on the company's goals, and identifying and selling to customers were the method of achieving those goals. However,today the customer is king and therefore the focus is shifting to accommodatethis change. The road to success - or failure - is now an expressway, and companies must be ready to accelerate,tum, or stop quickly. Flexibilityand manoeuvrabilitymean a great deal in an increasinglycompetitivemarketplace(Gabe & Goldberg, 1999). What makes a sales team effective in today's competitive global market? What are the key drivers of success in pharmaceutical sales team effectiveness? The most prominent trend in the US market is customer focus, and the most prominent issue is the recruitment and retention of top performers. Today's focus on relationship building may have occurred in part because companies found that their relationships were less than ideal. Nearly 60% of US pharmaceutical companies use customersatisfaction results, among other measurements, to determine the effectiveness of their sales force. A sales force that can make the transition from selling the product to selling the solution - which is the essence of customer focus - has a better chance of earning customer confidence and "partnering" (Gabe & Goldberg, 1999). To isolate factors that make a pharmaceutical sales representative effective is not easy. The best pharmaceutical representatives have excellent selling skills and behaviours, exhibit consistent performance, build networks, contribute to their teams, focus on the most profitable accounts, open new accounts, and win customer loyalty. How does one identify top pharmaceutical salespeople? Look for the representatives with the ability to learn continuously from experience, to take full responsibility for professional development, to size up each situation, and to apply the most effective skills for that encounter. Most often, they will be the ones using consultative and adaptive selling dialogue techniques (Snader, 2002). According to the study, it was evident that the following effectiveness criteria or selling task characteristics have a definite impact on sales force effectiveness and in turn should be part of every salesperson's capabilities: territory management, objection handling, business planning, adaptive selling, customer focus, knowledge, service, selling skills and training.
AFRIKAANSE OPSOMMING: In die verlede was farmaseutiese maatskappye geneig om hul besigheid van binne na buite te ontleed. Die belangrikste fokuspunt was die maatskappy se doelwit en die identifisering van, en verkope aan hul kliënte die middel tot die doelom hierdie doelwitte te bereik. Vandag, daarenteen kraai die kliënt koning en die fokuspunt het verskuif om by hierdie verandering aan te pas. Die verskil tussen die sukses en mislukking van 'n maatskappy sal afhang van die buigsaamheid en stuurbaarheid van die maatskappy om gereed te wees vir enige aksie in hierdie toenemend mededingende mark (Gabe & Goldberg, 1999). Wat maak 'n verkoopspan doeltreffend in vandag se mededingende globale mark? Wat is die sleutel eienskappe wat sukses sal waarborg vir 'n farmaseutiese verkoopspan? Die belangrikste neiging in die Amerikaanse mark is kliënte-fokus en die mees prominente kwessie is die werwing en behoud van die top presteerders. Die fokusverskuiwing na die verhouding tussen die verkoopsverteenwoordiger en die kliënt het plaasgevind nadat maatskappye besef het hulle het nie ideale verhoudings met hulle kliënte nie. Nagenoeg 60% van alle Amerikaanse farmaseutiese maatskappye gebruik onder andere ook resultate van kliënte-tevredenheid vraelyste as 'n maatstaf om die doeltreffendheid van hulle verkoopspan te bepaal. 'n Verkoopspan wat in plaas van 'n produk verkoop eerder aan die kliënt 'n oplossing vir sy spesifieke probleem bied - wat die kern van 'n kliënt-gefokusde benadering is - skep vertroue by die kliënt en lei tot 'n suksesvolle vennootskap tussen die partye (Gabe & Goldberg, 1999). Dit is baie moeilik om eienskappe te identifiseer wat 'n farmaseutiese verteenwoordiger se doeltreffendheid verseker. Die beste farmaseutiese verkoopsverteenwoordigers gebruik uitstekende verkoopstegnieke, bou netwerke, is goeie spanlede, fokus op die mees winsgewendste kliënte, wen nuwe kliënte en die lojaliteit van hulle kliënte. Hoe word top farmaseutiese verkoopspersone dan geïdentifiseer? Kyk uit vir die verteenwoordiger wat die vermoeë het om te leer uit ondervinding, wat volle verantwoordelikheid neem vir sy persoonlike ontwikkeling, wat elke situasie ontleed en dan die toepaslike vaardighede gebruik vir die spesifieke situasie. Meestal sal dit die verteenwoordigers wees wat konsulterende en adaptiewe dialoogtegnieke gebruik (Snader, 2002). Volgens die studie was dit duidelik dat die volgende kriteria vir doeltreffende verkope of verkoopseienskappe 'n defnitiewe impak het op 'n verkoopsspan se doeltreffendheid en dus deel moet uitmaak van elke verkoopspersoon se vermoë: Areabestuur, die hantering van objeksies, besigheidsbeplanning, 'n adaptiewe verkoopstyl, 'n kliënt gefokusde benadering, kennis, diens en opleiding.
Books on the topic "Pharmaceutical industry Australia Evaluation"
1
Hartog, Robert. German and Swiss drug supplies to the Third World: Survey and evaluation of pharmacological rationality. [Amsterdam, The Netherlands]: BUKO Pharma-Kampagne, 1989.
Find full text
2
1948-, Kennedy Tony, ed. Pharmaceutical project management. New York: M. Dekker, 1998.
Find full text
3
Foundation, India Brand Equity. The Best of India: Rx India, pharmacy of the world. Gurgaon: India Brand Equity Foundation, 2010.
Find full text
4
Lalitha, N. India's pharmaceutical industry in WTO regime: A SWOT analysis. Ahmedabad: Gujarat Institute of Development Research, 2002.
Find full text
5
Wadding, Patrick M. Supplier selection and evaluation models and their use in the Irish pharmaceutical industry. Dublin: University College Dublin, 1993.
Find full text
6
D, Edwards Lionel, ed. Principles and practice of pharmaceutical medicine. 2nd ed. Chichester, West Sussex: John Wiley & Sons, 2007.
Find full text
7
Pitts, Eamonn. Evaluation of marketing opportunities for dairy product ingredients in the medical pharmaceutical market. Dublin: An Foras Taluntais, 1987.
Find full text
8
Principles and practice of pharmaceutical medicine. 3rd ed. Oxford, UK: Wiley-Blackwell, 2010.
Find full text
9
Force, Western Australia Electricity Reform Task. Discussion paper on the reform of the electricity supply industry in Western Australia. [Perth?]: Electricity Reform Task Force, 2002.
Find full text
10
Impurities evaluation of pharmaceuticals. New York: Marcel Dekker, 1998.
Find full textBook chapters on the topic "Pharmaceutical industry Australia Evaluation"
1
Epp, Joanne, Bonny Parkinson, and Sally Hawse. "Health System Sustainability: The Pharmaceutical Benefits Scheme in Australia." In Industry and Higher Education, 13–44. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-0874-5_2.
Full text
2
Smith, G. Teeling. "Economic Aspects of Toxicity for the Pharmaceutical Industry." In The Future of Predictive Safety Evaluation, 79–87. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4139-7_6.
Full text
3
Schach Von Wittenau, M. "Acute Toxicology Viewed from the Pharmaceutical Industry." In The Contribution of Acute Toxicity Testing to the Evaluation of Pharmaceuticals, 42–45. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70390-4_6.
Full text
4
Eisele, Jeffrey, Amy Racine, and Mauro Gasparini. "Evaluation of the Decimal Reduction Time of a Sterilization Process in Pharmaceutical Production." In Applied Statistics in the Pharmaceutical Industry, 457–74. New York, NY: Springer New York, 2001. http://dx.doi.org/10.1007/978-1-4757-3466-9_18.
Full text
5
Taylor, D. "The Economic Milieu in Europe: View of the Pharmaceutical Industry." In Socioeconomic Evaluation of Drug Therapy, 23–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-61366-1_4.
Full text
6
Champey, Yves. "The Organisation of New Drug Evaluation in the Pharmaceutical Industry." In Early Phase Drug Evaluation in Man, 99–109. London: Macmillan Education UK, 1990. http://dx.doi.org/10.1007/978-1-349-10705-6_8.
Full text
7
Gradnik, Roberto. "Drug Design in Cardiology: The Pharmaceutical Industry Point of View." In PET for Drug Development and Evaluation, 215–18. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0429-6_20.
Full text
8
Raju, Geo, Harpreet Singh, Prabir Sarkar, and Ekta Singla. "A Framework for Evaluation of Environmental Sustainability in Pharmaceutical Industry." In Lecture Notes in Mechanical Engineering, 797–806. New Delhi: Springer India, 2016. http://dx.doi.org/10.1007/978-81-322-2740-3_77.
Full text
9
Nandy, Mithun. "Evaluation of Financial Performance in Global Context." In Relationship between R&D and Financial Performance in Indian Pharmaceutical Industry, 139–44. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-6921-7_6.
Full text
10
Li, Wanying, Yufang He, Yanyin Cui, Zining Zhang, Fang Xia, and Ziying Xu. "Comprehensive Evaluation of Innovation Efficiency of Jilin Province Pharmaceutical Manufacturing Industry Based on Radar Map Feature Vector Algorithm." In Proceedings of the 11th International Conference on Computer Engineering and Networks, 604–15. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-6554-7_66.
Full textConference papers on the topic "Pharmaceutical industry Australia Evaluation"
1
Karanges, Emily, Natasha Ting, Lisa Parker, Alice Fabbri, and Lisa Bero. "19 Pharmaceutical industry payments to thought leaders in cardiovascular disease and diabetes." In Preventing Overdiagnosis Abstracts, December 2019, Sydney, Australia. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/bmjebm-2019-pod.33.
Full text
2
Miranda, Rebeca, Giovanna Monteiro, Luiza Vasconcellos, Samara Silva, and Luciana Costa. "Evaluation of stenotrophomonas maltophilia biofilm tolerance to disinfectants used in a pharmaceutical industry." In International Symposium on Immunobiologicals. Instituto de Tecnologia em Imunobiológicos, 2022. http://dx.doi.org/10.35259/isi.2022_52295.
Full text
3
Zhao, Xianglian, and Juan Du. "Construction and application of performance evaluation system for Chinese pharmaceutical manufacturing industry from stakeholders' perspective." In 2017 International Conference on Grey Systems and Intelligent Services (GSIS). IEEE, 2017. http://dx.doi.org/10.1109/gsis.2017.8077728.
Full text
4
Ohtake, S., A. Langford, and B. Luy. "Current needs of the pharmaceutical industry: opportunities and challenges for implementing novel drying technologies." In 21st International Drying Symposium. Valencia: Universitat Politècnica València, 2018. http://dx.doi.org/10.4995/ids2018.2018.8354.
Full textAbstract:
Commercial drying methods are limited either by high production costs or significant quality loss due to process-related stresses. The near-ubiquitous use of freeze-drying in the pharmaceutical industry makes it the standard to which other drying technologies are compared. However, the shortcomings of lyophilization warrant evaluation of new techniques and the benefits they offer, such as compatibility with continuous manufacturing. Novel drying technologies must also overcome barriers to commercial implementation including, but not limited to, scalability and integration into a GMP environment. There remain several opportunities for further research which direct focus and investment strategy for the next generation pharmaceutical drying technologies. Keywords: pharmaceuticals; manufacturing technology; implementation; lyophilization; scalability
5
Silva, Wallace, and Miguel Herrera. "Use of soft modeling based on system dynamics for evaluation of partnerships for productive development focusing on technology transfer pharmaceutical industry." In International Symposium on Immunobiologicals. Instituto de Tecnologia em Imunobiológicos, 2022. http://dx.doi.org/10.35259/isi.2022_52165.
Full text
6
Schaffer, Dennis A. "Simulation Modeling: Risk Free Evaluation of Performance Alternatives." In ASME 1998 Citrus Engineering Conference. American Society of Mechanical Engineers, 1998. http://dx.doi.org/10.1115/cec1998-4405.
Full textAbstract:
Computer simulation is not a new technology; it has been used extensively by military, academic, and industrial organizations since the 1950’s for everything from critical strategic planning to validation of black hole and expanding universe theories. Early projects were hampered by excessive cost, cumbersome hardware, and complex programming but recent advances in personal computer power and application software have provided a basis for rapid advancement of simulation as a powerful, cost effective, risk free tool that can be used to analyze and improve any operating system. Computer simulation modeling is now used throughout the world as a primary decision making tool by all major automotive manufactures, can makers, financial institutions, pharmaceutical companies, and food processors. The Florida citrus industry is faced with a continuous challenge to cut operating costs while improving quality and service, and we are asked to meet the challenge on a severely limited budget with utmost speed. We know changes must be made, and we even have a good idea what they are, but we are not sure which changes should be made first, or if they will really work as well as we think. We also know that trial and error methods of testing changes can be financially risky and disruptive to the existing process. A wrong decision to proceed with trial and error testing can have extreme consequences for both the decision-maker and the business, and many excellent ideas are never implemented due to a justified “fear of failure”. Simulation allows many ideas to be tested in a greatly compressed time frame without committing capital, wasting time, or disrupting the process. Simulation promotes creative thinking and provides credible data for informed decision-making at all levels of an operation that cannot be obtained by any other method. Paper published with permission.
7
Barbosa, Fábio C. "LNG Use in Freight Rail Industry as an Economic and Environmental Driver: A Technical, Operational and Economic Assessment." In 2017 Joint Rail Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/jrc2017-2233.
Full textAbstract:
Freight rail carriers have been continuously challenged to reduce costs and comply with increasingly stringent environmental standards, into a continuously competing and environmentally driven industry. In this context, current availability and relative abundance of clean and low cost non conventional gas reserves have aroused a comprehensive reevaluation of rail industry into fuel option, especially where freight rail are strongly diesel based. Countries in which rail sector is required to play an important role in transport matrix, where fuel expenditures currently accounts for a significant share of operational costs, like Australia, Brazil, United States and other continental countries, can be seen as strong candidates to adopt fuel alternatives to diesel fueled freight railways. Moreover, from an environmental perspective, the use of alternative fuels (like natural gas) for locomotive traction may allow rail freight carriers to comply with emission standards into a less technologically complex and costly way. In this context, liquefied natural gas (LNG) fueled freight locomotives are seen as a strong potential near-term driver for natural gas use in rail sector, with its intrinsic cost and environmental benefits and with the potential to revolutionize rail industry much like the transition from steam to diesel experienced into the fifties, as well as the more recent advent of use of alternating current diesel-electric locomotives. LNG rail fueled approach has been focused on both retrofitting existing locomotive diesel engines, as well as on original manufactured engines. Given the lower polluting potential of natural gas heavy engines, when compared to diesel counterparts, LNG locomotives can be used to comply with increasingly restrictive Particulate Matter (PM) and Nitrogen Oxides (NOx) emission standards with less technological complexity (engine design and aftertreatment hardware) and their intrinsic lower associated costs. Prior to commercial operation of LNG locomotives, there are some technical, operational and economic hurdles that need to be addressed, i.e. : i) locomotive engine and fuel tender car technological maturity and reliability improvement; ii) regulation improvement, basically focused on operational safety and interchange operations; iii) current and long term diesel - gas price differential, a decisive driver, and, finally, iv) LNG infrastructure requirements (fueling facilities, locomotives and tender car specifications). This work involved an extensive research into already published works to present an overview of LNG use in freight rail industry into a technical, operational and economical perspective, followed by a critical evaluation of its potential into some relevant freight rail markets, such as United States, Brazil and Australia, as well as some European non electrified rail freight lines.
8
Blumberg, Matthew, Elizabeth Tellier, Dhyanjyoti Deka, and Tongming Zhou. "Experimental Evaluation of Vortex Induced Vibration Response of Straked Pipes in Tandem Arrangements." In ASME 2012 31st International Conference on Ocean, Offshore and Arctic Engineering. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/omae2012-83772.
Full textAbstract:
Vortex induced vibration (VIV) due to steady current flow can be a significant driver in the design of offshore riser systems, affecting riser global configuration, component details and overall subsea architecture. Helical strakes are known to reduce VIV but the degree of effectiveness can vary considerably depending on strake pitch, fin height and more importantly, current flow regime. In addition, the amplitude of VIV and the effectiveness of VIV suppression strakes depends on the inclination of flow to the riser (incidence angle) and presence of wake effects from adjacent risers. Test and field data regarding suppression of riser VIV by strakes is not extensively available in the public domain. This is primarily due to the proprietary nature of the tests conducted in industry. In this paper, a program of testing is devised to better understand strake effectiveness as a function of current incidence angle and the presence of adjacent risers. Experiments have been conducted on single and tandem pipe arrangements in air in order to evaluate strake suppression efficiency. Aluminium cylinders are tested in a wind tunnel in the structures laboratory of The University of Western Australia (UWA). Two sets of experiments are conducted: the first to evaluate cylinder VIV response at angles of incidence ranging from 30 to 90 degrees and the second to evaluate VIV response of the downstream pipe in a dual pipe arrangement with varying spacing between the pipes. In both cases the bare cylinders are first tested at varying flow speeds. Helical strakes are then added to the single cylinder, and downstream cylinder in the tandem pipe test, and the vibration response is recorded at varying flow speeds. From the experimentation, it can be seen that downstream cylinder motions are amplified by wake induced instability. This phenomenon is of particular concern for tightly spaced top-tensioned risers (TTR) in wellbays of tension leg platforms (TLP) and deep draft floaters. The VIV motion of the downstream, bare, wake-affected pipe, is magnified to approximately 1.3–2 times the motion of a single bare pipe. When strakes are added to the downstream cylinder, the magnification factor of the downstream cylinder response is largely increased due to the wake of the upstream bare cylinder. However, the actual VIV motions of the downstream cylinder are largely reduced when strakes are incorporated. The present work demonstrates that helical strakes provide an effective means of suppressing vortex induced vibrations of risers in riser arrays, though the degree of effectiveness is reduced in a downstream tubular compared to suppression levels for single pipes.
9
McAlpine, Hamish C., Ben Hicks, and Stephen Culley. "Improving Re-Use of Informal Information Through the Creation of an Engineering Electronic Logbook (EEL): A Demonstrator." In ASME 2009 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. ASMEDC, 2009. http://dx.doi.org/10.1115/detc2009-87308.
Full textAbstract:
Electronic logbooks (e-logbooks or e-notebooks) are used extensively in other domains — most notably the pharmaceutical industry — to good effect. However, despite a number of attempts over the last decade, engineers have resisted making the transition from their trusted paper logbooks. Reasons for this include a lack of understanding about how and why engineers use logbooks and a lack of appropriate software and hardware. In order to explore these issues, user-centric studies of engineers and their logbooks have been undertaken. From these studies a set of fundamental requirements have been developed that provide the basis for the creation of an Engineering Electronic Logbook (EEL). A demonstrator based on the Tablet PC platform to evaluate the information management aspects these requirements is then presented, together with details of how it is currently being evaluated. The contribution of this paper is a new information management strategy for e-logbooks — which has been derived from analysing existing paper-based logbooks and the note-taking practices of engineers — and its embodiment in a demonstrator for evaluation.
10
Bray, Don E., and G. S. Gad. "Establishment of an NDE Center at the Papua New Guinea University of Technology: Scope and Objectives." In ASME 1997 Turbo Asia Conference. American Society of Mechanical Engineers, 1997. http://dx.doi.org/10.1115/97-aa-065.
Full textAbstract:
Papua New Guinea lies just north of Australia (Fig. 1). It is a developing island nation, with 462,839 km of land area, a population of 3.9 million people, and vast natural resources (Compton’s Interactive Encyclopedia, 1996). It is the largest island in the Oceania region of the world, which also includes Fiji, the Solomon Islands and Vanuatu. Most of these islands share similar resources, and prudent development of the resources requires utilization of nondestructive evaluation (NDE). NDE provides the means for flaw detection and size assessment, as well as evaluation of material degradation such as corrosion and hydrogen attack. These are factors which affect the service life of components and systems. Being aware of the state of degradation of these components and systems will enable cost effective maintenance, and reduce costly and dangerous failures. Recognizing the need for NDE expertise, the Papua New Guinea University of Technology at Lae has initiated a Center for Nondestructive Evaluation. Once operational, the center should serve the entire Oceania region, and provide resources, trained students and expertise that will enable the growth of the NDE industry within that area. It is widely accepted that NDE adds value to a product or process, not just cost. The amount of value is directly related to the engineering education of the personnel making NDE decisions. The growth of the NDE industry in these South Pacific Islands will add to the economy, as well as aid in the further creation of a population of engineers who are well educated in NDE.
Reports on the topic "Pharmaceutical industry Australia Evaluation"
1
Agu, Monica, Zita Ekeocha, Stephen Robert Byrn, and Kari L. Clase. The Impact of Mentoring as a GMP Capability Building Tool in The Pharmaceutical Manufacturing Industry in Nigeria. Purdue University, December 2012. http://dx.doi.org/10.5703/1288284317447.
Full textAbstract:
Good Manufacturing Practices (GMP), a component of Pharmaceutical Quality Systems, is aimed primarily at managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety and efficacy of products. Provision of adequate number of personnel with the necessary qualifications/practical experience and their continuous training and evaluation of effectiveness of the training is the responsibility of the manufacturer. (World Health Organization [WHO], 2014; International Organization for Standardization [ISO], 2015). The classroom method of training that has been used for GMP capacity building in the pharmaceutical manufacturing industry in Nigeria over the years, delivered by experts from stringently regulated markets, have not yielded commensurate improvement in the Quality Management Systems (QMS) in the industry. It is necessary and long over-due to explore an alternative training method that has a track record of success in other sectors. A lot of studies carried out on mentoring as a development tool in several fields such as academia, medicine, business, research etc., reported positive outcomes. The aim of this study was to explore mentoring as an alternative GMP training method in the pharmaceutical manufacturing industry in Nigeria. Specifically, the aim of this study was to evaluate the impact of mentoring as a GMP capability building tool in the pharmaceutical manufacturing industry in Nigeria, with focus on GMP documentations in XYZ pharmaceutical manufacturing company located in South-Western region of Nigeria. The methodology comprised gap assessment of GMP documentation of XYZ company to generate current state data, development of training materials based on the identified gaps and use of the training materials for the mentoring sessions. The outcome of the study was outstanding as gap assessment identified the areas of need that enabled development efforts to be targeted at these areas, unlike generic classroom training. The mentees’ acceptance of the mentoring support was evident by their request for additional training in some other areas related to the microbiology operations that were not covered in the gap assessment. This result portrays mentoring as a promising tool for GMP capacity building, but more structured studies need to be conducted in this area to generate results that can be generalized.